Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose ambroxol plus enzyme replacement therapy in Gaucher disease (Phase I/II, open-label)
KCT0003218Phase 2Recruiting
- Sponsor
- ISU Abxis Co., Ltd.
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ambroxol in Gaucher disease (GD), sponsored by ISU Abxis Co., Ltd.. Started Mar 2015; status: recruiting.
02
Drugs
ambroxol
03
Conditions
Gaucher disease (GD)
Beyond the preview
Go deeper on KCT0003218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003218.